Breaking News Instant updates and real-time market news.

M

Macy's

$35.57

-1.23 (-3.34%)

, CBL

CBL & Associates

$11.69

-0.11 (-0.93%)

07:39
10/17/16
10/17
07:39
10/17/16
07:39

Macy's sticks with decision to open stores on Thanksgiving, CNBC reports

Macy's (M) is sticking with its decision to open on Thanksgiving Day, CNBC reports. Even as many malls and retailers won't open, the retail giant is expected to open its doors at 5 p.m. that day, an hour earlier than last year, the report says. This year, many retailers, including TJ Maxx (TJX) and Nordstrom (JWN), and mall operators, including the Mall of America and CBL & Associates (CBL), are closing their properties on Thanksgiving. Reference Link

M

Macy's

$35.57

-1.23 (-3.34%)

CBL

CBL & Associates

$11.69

-0.11 (-0.93%)

TJX

TJX

$74.23

-0.24 (-0.32%)

JWN

Nordstrom

$53.63

-0.05 (-0.09%)

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

M Macy's
$35.57

-1.23 (-3.34%)

09/14/16
09/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying an attractive free cash flow and dividend yield makes the risk/reward attractive at current levels. 2. Fifth Third (FITB) upgraded to Buy from Neutral at Compass Point. 3. F5 Networks (FFIV) upgraded to Outperform from Perform at Oppenheimer with analyst Ittai Kidron saying the company has several potential drivers that could drive year-over-year product revenue growth back into positive territory in fiscal 2017. 4. Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus with analyst John Staszak saying that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. 5. DeVry (DV) upgraded to Outperform from Market Perform at Barrington with analyst Alexander Paris saying management's near-term goal is stabilizing revenue at DeVry University growing enrollment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
GUGG
09/30/16
INITIATION
Target $45
GUGG
Buy
Macy's initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Macy's with a Buy and a $45 price target saying shares offer a compelling risk reward ratio due to the company's healthy balance sheet, 4.2% dividend yield, and strong free cash flow.
09/28/16
FBCO
09/28/16
DOWNGRADE
Target $40
FBCO
Neutral
Macy's downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Michael Exstein downgraded Macy's (M) to Neutral saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. The analyst recommends swapping into Dillard's (DDS), which he upgraded this morning to Outperform. Exstein remains Underweight the Department Store space and keeps a $40 price target for shares of Macy's.
CBL CBL & Associates
$11.69

-0.11 (-0.93%)

08/29/16
08/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. T-Mobile (TMUS) upgraded to Outperform from Market Perform at Wells Fargo, with analyst Jennifer Fritzsche saying the company's free cash flow should ramp significantly in 2017. T-Mobile should also see continued positive momentum in subscriber growth and be helped by M&A speculation post the Presidential election, said Fritzsche, who raised her price target range for the shares to $52-$54 from $48-$50. 2. KLA-Tencor (KLAC) upgraded to Outperform from Market Perform at Cowen by analyst Timothy Arcuri, who views the shares as "too interesting to ignore" regardless of the Lam Research (LRCX) deal outcome. KLA's risk/reward, even if the deal breaks, is now 3:1 to the upside, which is hard to find in semis, Arcuri tells investors in a research note. 3. Allegheny Technologies (ATI) upgraded to Buy from Hold at Deutsche Bank, with Deutsche Bank analyst Jorge Beristain saying leverage concerns have eased following the closure of the company's Rowley facility. Management is acting to exit low-margin stainless products, said Beristain. 4. CBL & Associates (CBL) upgraded to Buy from Hold at Jefferies, as analyst Omotayo Okusanya thinks "several issues" that have been an overhang on the shares are now resolved or are in the process of resolution. The company's portfolio quality is rising while its balance sheet is in better shape, Okusanya tells investors. 5. AstraZeneca upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/16
JEFF
08/29/16
UPGRADE
Target $16
JEFF
Buy
CBL & Associates upgraded to Buy from Hold at Jefferies
Jefferies analyst Omotayo Okusanya upgraded CBL & Associates to Buy saying "several issues" at have been an overhang on the shares are now resolved or are in the process of resolution. The company's portfolio quality is rising while its balance sheet is in better shape, Okusanya tells investors in a research note. The analyst raised his price target for the shares to $16 from $10.50.
07/15/16
KEYB
07/15/16
UPGRADE
Target $15
KEYB
Overweight
CBL & Associates upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jordan Sadler upgraded CBL & Associates to Overweight with a $15 price target saying the company has "significant valuation support" and its dividend is well-covered.
07/14/16
KEYB
07/14/16
UPGRADE
KEYB
Overweight
CBL & Associates upgraded to Overweight from Sector Weight at KeyBanc
TJX TJX
$74.23

-0.24 (-0.32%)

08/17/16
WELS
08/17/16
NO CHANGE
WELS
TJX 'bull thesis still in play,' says Wells Fargo
After TJX yesterday reported stronger than expected Q2 results but provided lower than expected Q3 guidance and the stock fell nearly 6%, Wells Fargo says that the wage pressures cited by the company are not worrisome. The firm thinks that the company's "top line fundamentals remains some of the strongest" in its sector Wells expects analysts to reduce their estimates for the company due to the wage pressures, but it recommends buying the shares "on any prolonged pullback" and keeps an Outperform rating.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Buy
TJX coverage assumed with a Buy at Guggenheim
Guggenheim analyst Robert Drbul assumed coverage on TJX with a Buy and an $85 price target. He believes the off-price sector should continue to gain market share due to shifts in both vendor and consumer preferences and expects TJX to be one of the main beneficiaries.
08/17/16
RHCO
08/17/16
NO CHANGE
RHCO
TJX should be bought on weakness, says SunTrust
After TJX yesterday reported stronger than expected Q2 results but provided lower than expected Q3 guidance and the stock fell nearly 6%, SunTrust analyst Pamela Quintiliano says that the company's guidance is conservative. She noted that the company's results so far this quarter have been "solid," and says that it is well-positioned for continued market share gains. The analyst recommends buying the stock on weakness.
08/17/16
WEDB
08/17/16
NO CHANGE
WEDB
TJX fundamentals still strong, says Wedbush
After TJX yesterday reported stronger than expected Q2 results but provided lower than expected Q3 guidance and the stock fell nearly 6%, Wedbush analyst Morry Brown remains upbeat on the company's fundamentals which he says have not changed. The analyst says that the wage pressures and adverse foreign exchange fluctuations reported by the company aren't new. Brown expects the company's SSS to continue to outperform that of its peers. He raised his price target on the shares to $84 from $82 and keeps an Outperform rating.
JWN Nordstrom
$53.63

-0.05 (-0.09%)

08/15/16
RBCM
08/15/16
NO CHANGE
RBCM
Nordstrom results 'encouraging,' says RBC Capital
RBC Capital analyst Brian Tunick says he was "encouraged" by Nordstrom's better than expected Q2 results, and he is upbeat on the company's sales initiatives. However, he keeps a Sector Perform rating on the stock, citing valuation.
08/12/16
UBSW
08/12/16
NO CHANGE
Target $58
UBSW
Buy
Nordstrom price target raised to $58 from $44 at UBS
UBS raised its price target on Nordstrom to $58 from $44 following Q2 results. The firm cited improved Rack trends, raised guidance, and improved visibility. UBS reiterated its Buy rating on Nordstrom shares.
08/12/16
KEYB
08/12/16
NO CHANGE
KEYB
Nordstrom price target raised to $65 from $52 at KeyBanc
KeyBanc says that Nordstrom reported "strong" Q2 results, while the company's set up is "increasingly favorable." The firm thinks that the stock offers one of the best risk/reward ratios in its softlines/apparel coverage. It reiterates an Overweight rating on the shares.
09/30/16
GUGG
09/30/16
INITIATION
Target $60
GUGG
Buy
Nordstrom coverage assumed with a Buy at Guggenheim
Guggenheim analyst Robert Drbul coverage assumed Nordstrom with a Buy and a $60 price target.

TODAY'S FREE FLY STORIES

DHT

DHT Holdings

$4.60

-0.05 (-1.08%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
DHT Holdings announces delivery of two VLCCs from BW Group »

DHT Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFR

Colony Starwood Homes

$34.82

0.12 (0.35%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Initiation
Colony Starwood Homes initiated  »

Colony Starwood Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
AkzoNobel says will 'carefully review' PPG's third unsolicited proposal »

Akzo Nobel N.V. (AKZOY)…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.26

-0.04 (-0.39%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Initiation
Playa Hotels & Resorts initiated  »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

FLR

Fluor

$50.58

0.09 (0.18%)

, BP

BP

$34.00

-0.15 (-0.44%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
Fluor awarded offshore compression platform FEED by BP »

Fluor (FLR) announced…

FLR

Fluor

$50.58

0.09 (0.18%)

BP

BP

$34.00

-0.15 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:05
04/24/17
04/24
07:05
04/24/17
07:05
Hot Stocks
Paratek, Zai Lab announce collaboration for Omadacycline in China »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Paratek highlights potential for omadacycline to provide cost savings vs. SOC »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWLD

Buffalo Wild Wings

$161.75

-2 (-1.22%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Buffalo Wild Wings announces filing of proxy materials »

Buffalo Wild Wings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

GWW

Grainger

$195.15

-0.81 (-0.41%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Downgrade
Grainger rating change  »

Grainger downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 19

    Jul

  • 17

    Oct

  • 24

    Jan

ATEC

Alphatec

, CAE

CAE

$15.21

-0.06 (-0.39%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Conference/Events
American Association of Neurological Surgeons to hold annual meeting »

2017 AANS Annual…

ATEC

Alphatec

CAE

CAE

$15.21

-0.06 (-0.39%)

EDGE

Edge Therapeutics

$9.02

-0.02 (-0.22%)

MDT

Medtronic

$80.48

-0.54 (-0.67%)

NUVA

NuVasive

$75.02

-0.68 (-0.90%)

SYK

Stryker

$132.94

0.18 (0.14%)

VRTX

Vertex

$116.70

-0.56 (-0.48%)

SYNA

Synaptics

$50.76

-0.34 (-0.67%)

NVIV

InVivo Therapeutics

$3.90

-0.35 (-8.24%)

LMAT

LeMaitre

$25.14

-0.23 (-0.91%)

MZOR

Mazor Robotics

$35.68

0.64 (1.83%)

OFIX

Orthofix

$38.95

0.33 (0.85%)

SSNLF

Samsung

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

SNE

Sony

$33.68

0.85 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 18

    May

  • 24

    May

  • 25

    May

  • 06

    Jun

AMRI

Albany Molecular

$15.82

0.04 (0.25%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Denovo obtains license to Albany Molecular's liafensine »

Denovo Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

OPB

Opus Bank

$20.80

0.6 (2.97%)

07:03
04/24/17
04/24
07:03
04/24/17
07:03
Earnings
Opus Bank reports Q1 EPS ex-items 24c, consensus 27c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 15

    May

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:03
04/24/17
04/24
07:03
04/24/17
07:03
Hot Stocks
Paratek: Omadacycline 'effective' against most common skin infections, MRSA »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$79.28

-0.15 (-0.19%)

07:02
04/24/17
04/24
07:02
04/24/17
07:02
Recommendations
CVS Health analyst commentary  »

JPMorgan a buyer of CVS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

MTNB

Matinas BioPharma

$2.93

0.06 (2.09%)

07:02
04/24/17
04/24
07:02
04/24/17
07:02
Hot Stocks
Matinas BioPharma presents 'positive' preclinical data of DNA vaccines at ECCMID »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

PDLI

PDL BioPharma

$2.02

-0.03 (-1.46%)

, MRK

Merck

$61.89

-0.66 (-1.06%)

07:02
04/24/17
04/24
07:02
04/24/17
07:02
Hot Stocks
PDL BioPharma settles Keytruda patent infringement suit with Merck »

PDL BioPharma (PDLI)…

PDLI

PDL BioPharma

$2.02

-0.03 (-1.46%)

MRK

Merck

$61.89

-0.66 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 09

    Jun

  • 14

    Jun

ERII

Energy Recovery

$8.18

0.03 (0.37%)

07:01
04/24/17
04/24
07:01
04/24/17
07:01
Hot Stocks
Energy Recovery awareded $3M in orders for its PXTM technology »

Energy Recovery announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$10.38

0.41 (4.11%)

07:01
04/24/17
04/24
07:01
04/24/17
07:01
Hot Stocks
RedHill Biopharma announces enrollment of last patient in Bekinda Phase II study »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

NVS

Novartis

$73.40

-0.22 (-0.30%)

, LLY

Eli Lilly

$81.89

-0.05 (-0.06%)

07:00
04/24/17
04/24
07:00
04/24/17
07:00
Periodicals
Novartis tests Alzheimer's drugs on people who don't yet have disease, WSJ says »

Novartis (NV) is testing…

NVS

Novartis

$73.40

-0.22 (-0.30%)

LLY

Eli Lilly

$81.89

-0.05 (-0.06%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 07

    May

  • 06

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

SONC

Sonic

$24.91

0.63 (2.59%)

06:59
04/24/17
04/24
06:59
04/24/17
06:59
Upgrade
Sonic rating change  »

Sonic upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

06:59
04/24/17
04/24
06:59
04/24/17
06:59
Upgrade
Analog Devices rating change  »

Analog Devices upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

APTS

Preferred Apartment

$14.29

0.05 (0.35%)

06:57
04/24/17
04/24
06:57
04/24/17
06:57
Hot Stocks
Preferred Apartment acquires 80,018 square foot shopping center in Atlanta »

Preferred Apartment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

MDEVF

Melco International

06:56
04/24/17
04/24
06:56
04/24/17
06:56
Downgrade
Melco International rating change  »

Melco International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AU

AngloGold

$12.43

-0.08 (-0.64%)

06:53
04/24/17
04/24
06:53
04/24/17
06:53
Downgrade
AngloGold rating change  »

AngloGold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GFI

Gold Fields

$3.84

-0.08 (-2.04%)

06:53
04/24/17
04/24
06:53
04/24/17
06:53
Downgrade
Gold Fields rating change  »

Gold Fields downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.